Gary Palmer, MD
Gary joined Eisai in June of 2010 and is responsible for leading the U.S. and America’s Medical and Scientific Affairs Organization at Eisai across all therapeutic areas, including the Medical Strategy teams, Medical Science Liaisons, Clinical Operations for phase IIIb/IV projects, Scientific Communications and oversight of the Global Product Safety team.
Gary has been working in the pharmaceutical industry for 20 years and prior to joining Eisai worked for Bristol-Myers Squibb Inc., with responsibility for Global Medical Affairs from October 2009 until joining Eisai. Preceding this position within BMS, Gary was the Chief Medical Officer and Head of Medical Affairs for Europe, the Middle East and Africa for four years and was based in Paris, France.
Prior to BMS, he was with Pfizer Inc. for eight years, based in New York, in roles of increasing responsibility including Medical Director, Worldwide Team Leader for Lipitor, Group Director and Vice President in the Cardiovascular and Metabolic franchise, as well as Group Vice President for U.S. Managed Markets.
Gary has been involved in supporting a number of new product launches over the past five years (across therapeutic areas that include Oncology, Metabolic & Diabetes and Neuroscience) with a focus on enhancing launch effectiveness.